###begin article-title 0
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1)
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 2 3 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(NHERF1</italic>
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EBP50 </italic>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF</italic>
###xml 148 155 148 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">17q25.1</italic>
###xml 157 164 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 324 331 324 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 421 428 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 513 520 513 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 116 121 <span type="species:ncbi:9606">human</span>
Na+/H+ exchanger regulatory factor 1 (NHERF1, also known as EBP50 or NHERF) is a putative tumour suppressor gene in human breast cancer. Located at 17q25.1, NHERF1 is frequently targeted during breast tumourigenesis. Loss of heterozygosity (LOH) at the NHERF1 locus is found in more than 50% of breast tumours. In addition, NHERF1 is mutated in a subset of primary breast tumours and breast cancer cell lines. LOH at the NHERF1 locus is strongly associated with aggressive features of breast tumours, implicating NHERF1 as a haploinsufficiency tumour suppressor gene. However, the putative NHERF1 tumour suppressor activity has not been functionally verified.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 262 271 262 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
To confirm the NHERF1 tumour suppressor activity suggested by our genetic analyses, we used retrovirus-transduced short hairpin RNA (shRNA) to knock down NHERF1 expression in breast cancer cell lines MCF7 and T47D. These cells were then assessed for cell growth in vitro and in vivo. The control and NHERF1 knockdown cells were also serum-starved and re-fed to compare their cell cycle progression as measured by fluorescence-activated cell sorting analyses.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 405 406 405 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
We found that downregulation of the endogenous NHERF1 in T47D or MCF7 cells resulted in enhanced cell proliferation in both anchorage-dependent and -independent conditions compared with that of the vector control cells. NHERF1 knockdown T47D cells implanted at mammary fat pads of athymic mice formed larger tumours than did control cells. We found that serum-starved NHERF1 knockdown cells had a faster G1-to-S transition after serum re-stimulation than the control cells. Immunoblotting showed that the accelerated cell cycle progression in NHERF1 knockdown cells was accompanied by increased expression of cyclin E and elevated Rb phosphorylation level.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 335 340 <span type="species:ncbi:9606">human</span>
Our findings suggested that the normal NHERF1 function in mammary epithelial cells involves blockage of cell cycle progression. Our study affirmed the tumour suppressor activity of NHERF1 in breast which may be related to its regulatory effect on cell cycle. It warrants future investigation of this novel tumour suppressor pathway in human breast cancer which may turn up therapeutic opportunities.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 2 3 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EBP-50 </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF</italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">17q25.1</italic>
###xml 334 341 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 478 485 478 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 531 538 531 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 700 707 700 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 828 835 828 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
Na+/H+ exchanger regulatory factor 1 (NHERF1, also known as EBP-50 or NHERF) is a candidate tumour suppressor gene in human breast cancer [1]. We reported loss of heterozygosity (LOH) at the NHERF1 gene locus (17q25.1) in more than 50% of human breast tumours. Such loss is infrequent, however, in other tumour types, suggesting that NHERF1 is specifically targeted during mammary tumourigenesis. In a panel of breast tumours pre-screened for LOH, three intragenic mutations of NHERF1 were found (approximately 3%) [1]. LOH at the NHERF1 locus is positively correlated with aggressive features of breast tumours, including tumour size, grade, and stage. The association indicates a critical role for NHERF1 in mammary carcinogenesis, in which its putative suppressor activity is haploinsufficient. The haploinsufficiency of the NHERF1 gene may explain its relatively low frequency of intragenic mutations.
###end p 11
###begin p 12
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 152 154 152 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1081 1082 1081 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1083 1084 1083 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1091 1092 1088 1089 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1114 1115 1111 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1116 1117 1113 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1169 1170 1166 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1171 1173 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1215 1217 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1342 1344 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1345 1347 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1396 1398 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1431 1432 1425 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1474 1476 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1497 1499 1488 1490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1572 1582 1563 1573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vice versa</italic>
###xml 1650 1651 1641 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1652 1654 1643 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 186 191 <span type="species:ncbi:9606">Human</span>
The NHERF1 gene encodes an intracellular molecule that was initially found to be a cofactor necessary for cAMP-mediated inhibition of renal apical Na+/H+ exchanger isoform 3 (NHE3) [2]. Human NHERF1 is a 358-amino acid protein that shares high homologue at the modular structures with NHERF2 (also known as E3KARP or TKA1) [3]. Both contain two tandem PDZ (PSD-95/Dlg/ZO1) domains (PDZ-I and PDZ-II) at the amino-terminus and an ezrin-radixin-moesin (ERM)-interacting domain at the carboxyl-terminus. NHERF1 and NHERF2 are highly expressed in polarised epithelial cells and are differentially expressed in mammalian tissues [2]. NHERF1, the one more extensively studied, acts as an important regulator and integrator of multiple signaling pathways by virtue of its ability to bind to a variety of proteins through its PDZ domains and an ERM-interacting domain. Via its PDZ domains, NHERF1 specifically recognises carboxyl-terminal motif (S/T)XL, which is present in a number of transmembrane proteins other than NHE3, including cystic fibrosis transmembrane conductance regulator [4-6], beta2-adrenergic receptor [7,8], platelet-derived growth factor receptor (PDGFR) [9,10], and sodium bicarbonate co-transporter [11]. NHERF1 has also been shown to interact with a variety of intracellular proteins, including phospholipase C-beta isoforms [12,13], GRK6A (G protein-coupled receptor kinase 6A) [14], spleen tyrosine kinase (SYK) [1], YAP65 (Yes-associated protein 65-kDa) [15], and beta-catenin [16]. The proteins recognised by PDZ-I do not, however, bind to PDZ-II, and vice versa, indicating that the two PDZ domains have distinct binding motifs [4,14].
###end p 12
###begin p 13
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 185 188 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF2</italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF2 </italic>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
NHERF1 binds, via its ERM-binding domain, to ERM proteins, a family of actin cytoskeletal adaptor proteins [17,18]. One ERM family member is merlin, the product of neurofibromatosis-2 (NF2), a tumour suppressor gene implicated in predisposition to meningiomas and schwanomas [19,20]. The amino-terminus of the ERM family proteins (ERM domain) interacts with the ERM-binding domain of NHERF1 [17,18]. The interaction may be important for NHERF1 functions by connecting membrane transporters and actin cytoskeleton [21,22]. Like other ERM members, merlin interacts with NHERF1 through its amino-terminus ERM domain. Notably, more than 80% of NF2 mutations are located in this ERM domain [23], and the mutant merlin proteins display significantly lower binding affinity to NHERF1, suggesting that NHERF1 is related to merlin's suppressor activity.
###end p 13
###begin p 14
###xml 244 251 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 238 243 <span type="species:ncbi:9606">Human</span>
Among the multiple biologic pathways in which NHERF1 is involved, the signaling event that is most relevant to NHERF1 pathobiology in mammary gland is not known, nor is it certain that NHERF1 elicits tumour suppressor activity in breast. Human NHERF1 was earlier shown to be an oestrogen-inducible gene [24,25]. Based on a critical role of oestrogen in mammary development and the early-stage progression of breast cancer, NHERF1 was initially postulated as a mitogenic factor [22], which is not supported by our genetic evidence [1]. To clarify these contrasting views, we sought to determine whether the proliferation of breast cancer cells is affected by knockdown of NHERF1 expression.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Cell culture
###end title 16
###begin p 17
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 478 484 <span type="species:ncbi:9913">bovine</span>
Human breast tumour cell lines BT20, BT474, BT483, BT549, CAMA1, DU4475, HCC1428, HCC1954, MB157, MCF7, MDA-MB-134, MDA-MB-231, MDA-MB-330, MDA-MB-361, MDA-MB-415, MDA-MB-435S, MDA-MB-453, MDA-MB-468, SKBr3, T47D, and ZR75-1 were purchased from American Type Culture Collection (Manassas, VA, USA). The SUM149-PT line was a gift from Dr. Stephan Ethier (University of Michigan, Ann Arbor, MI, USA). All cell lines were cultured in recommended media supplemented with 10% foetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA).
###end p 17
###begin title 18
Knockdown of NHERF1 expression
###end title 18
###begin p 19
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1034 1037 1034 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1044 1047 1044 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 1177 1179 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
A vector-based short hairpin RNA (shRNA) method was used to generate MCF7 and T47D cells with inhibited NHERF1 expression. A two-step ligation method [26] was used to insert the interfering sequences into pBS/U6 (a gift from Dr. Yang Shi, Harvard Medical School, Boston, MA, USA). Two NHERF1 mRNA sequences corresponding to cDNA positions 786 and 910 were targeted. Oligonucleotide sequences for NHERF-786 were 5'-GGAGATACAGAAGGAGAACAGA-3' (oligo 1, forward), 5'-AGCTTCTGTTCTCCTTCTGTATCTCC-3' (oligo 1, reverse), 5'-AGCTTCTGTTCTCCTTCTGTATCTCCCTTTTTG-3' (oligo 2, forward), and 5'-AATTCAAAAAGGGAGATACAGAAGGAGAACAGA-3' (oligo 2, reverse). Oligonucleotide sequences for NHERF-910 were 5'-GGAAACTGACGAGTTCTTCAA-3' (oligo 1, forward), 5'-AGCTTTGAAGAACTCGTCAGTTTCC-3' (oligo 1, reverse), 5'-AGCTTTGAAGAACTCGTCAGTTTCCCTTTTTG-3' (oligo 2, forward), and 5'-AATTCAAAAAGGGAAACTGACGAGTTCTTCAA-3' (oligo 2, reverse). Interference sequences were verified by automated DNA sequencing. The hairpin loop sequences were then released by digesting with BamHI and EcoRI and subcloned into a retroviral vector pBabe-U6 (a gift from Dr. Jinsong Liu, M. D. Anderson Cancer Center, Houston, TX, USA) [27], yielding pBabe-U6/NHERF-786 and pBabe-U6/NHERF-910. Retroviruses were produced by transfecting packaging cells (amphotropic Phoenix) with pBabe-U6/NHERF-786, pBabe-U6/NHERF-910, or parental pBabe-U6, using Fugene 6 (Roche Applied Science, Indianapolis, IN, USA). The medium was collected 2 days after transfection. After centrifugation, the supernatant was then passed through a 0.45-mum filter. The retrovirus stock was stored at -80degreesC until use. Cultured MCF7 and T47D cells were infected with a virus cocktail (1 ml of retroviral stock, 2 ml of medium, and 4 mug of polybrene). The next day, the virus was removed and replaced with fresh medium that contained 0.5 mug/ml puromycin. Surviving cells were assessed for NHERF1 expression by immunoblotting.
###end p 19
###begin title 20
Cell growth assay
###end title 20
###begin p 21
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Thymidine incorporation assay was used to measure the DNA synthesis rate as described previously [26]. MCF7 and T47D cells cultured in 24-well plates were pulsed with 1 mCi [3H]-thymidine (3,000 Ci/mmol; PerkinElmer Life and Analytical Sciences, Inc., Shelton, CT, USA). After 5-hour labeling, non-incorporated tritium was removed by trichloroacetic acid washes. Acid-insoluble tritium was assessed by scintillation counting (microBeta Trilux 1450; Wallac, now PerkinElmer Life and Analytical Sciences, Inc.). The relative cell proliferation rate was obtained by dividing the counts from cells in which NHERF1 was downregulated by the ones from control cells. Experiments were repeated three times.
###end p 21
###begin p 22
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were conducted to measure the relative number of viable cells. Cells were seeded in 96-well cluster dishes at 2,500 cells per well with 100 mul of complete medium. At indicated time points, medium was replaced with 100 mul of fresh medium supplemented with 20 mul of 5 mg/ml MTT (Sigma-Aldrich, St. Louis, MO, USA). The incubation lasted for 2 hours before the medium was removed and cells dissolved in 100 mul of lysis buffer. Absorbance was measured using a multiSkan plate reader (Thermo Scientific, Waltham, MA, USA) at a wavelength of 570 nm. Experiments were repeated at least three times.
###end p 22
###begin title 23
Anchorage-independent growth
###end title 23
###begin p 24
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
Cells (1 x 104) were suspended in 1 ml of 1x culture medium that contained 0.35% agarose. The suspension was added on top of 4 ml of solidified 0.7% agarose. After the cells were set in agarose, 1 ml of fresh medium was added to cover the agarose. Assays were performed in triplicate. Plated cells were incubated for 20 days at 37degreesC before formed colonies larger than 50 mum in diameter were counted. Experiments were repeated three times.
###end p 24
###begin title 25
Assessment of cell cycle distribution
###end title 25
###begin p 26
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
Cultured cells (approximately 2 x 106) were trypsinised and washed twice with 1x phosphate-buffered saline (PBS). Cells were then fixed by being added drop-wise to 5 ml of ice-cold 80% ethanol while vortexing. After fixing for at least 1 hour at room temperature, the cells were stored at -20degreesC. Before being stained, the cells were washed with 1x PBS and incubated at 37degreesC for 30 minutes with propidium iodide (50 mug/ml; Sigma-Aldrich) in the presence of 10 mul of RNase A (10 mg/ml; Sigma-Aldrich). Cell cycle analysis was performed with an FACS station equipped with CellQuest (Becton Dickinson, Franklin Lakes, NJ, USA). At each cell cycle phase, the population was determined by computer model fitting (Verity Software House, Topsham, ME, USA).
###end p 26
###begin p 27
###xml 54 55 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 57 59 57 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 98 100 98 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
Serum starvation was used to synchronise MCF7 at the G0/G1 phase. MCF7 cells were seeded at 8 x 105 per 60-mm dish. After being cultured in complete medium overnight, cells were incubated with serum-free medium for 1 day. The cells were then re-fed with medium supplemented with 10% FBS for various time periods before being harvested for fluorescence-activated cell sorting (FACS) analyses.
###end p 27
###begin title 28
Experimental tumourigenicity assay
###end title 28
###begin p 29
###xml 461 462 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 681 683 677 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 38 47 <span type="species:ncbi:10090">nude mice</span>
###xml 212 217 <span type="species:ncbi:10090">mouse</span>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
Four- to five-week-old female athymic nude mice (Harlan, Indianapolis, IN, USA) were used for experimental tumourigenicity assays. To facilitate the establishment of xenografts of oestrogen-dependent cells, each mouse was inoculated subcutaneously with an oestrogen pellet (0.7 mg 17beta-estradiol per pellet; 60-day slow-release; Innovative Research of America, Sarasota, FL, USA). Two days after pellet implantation, equivalent amounts of T47D cells (1.5 x 106; Babe control or NHERF-910) resuspended in 100 mul of mixture (1:1 with un-supplemented media) of Matrigel (BD Biosciences, San Jose, CA, USA) were injected into each side of second-pair breast mammary fat pads (3 x 106 cells in total). Six weeks after injection, mice were euthanised by carbon dioxide, and the established tumours on both sides of mammary glands were dissected, pooled, and weighed. All procedures were performed according to the recommendations of the Institutional Animal Care and Use Committee.
###end p 29
###begin title 30
Immunoblotting
###end title 30
###begin p 31
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Immunoblottings were carried out essentially as described previously [28]. Antibodies used were NHERF1 (EXBIO Praha, Bestec, Czech Republic), Rb and p27 (BD Biosciences), cdk2 (Calbiochem, San Diego, CA, USA), cdk4 and cyclin D1 (Cell Signaling Technology, Inc., Danvers, MA, USA), cyclin E and beta-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and alpha-tubulin (Sigma-Aldrich).
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
NHERF1 expression in breast cancer cells
###end title 33
###begin p 34
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 495 497 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
We used immunoblotting to analyse the expression of NHERF1 in 22 breast cancer cell lines (Figure 1a), among which the origin of MDA-MB-435S was under debate [29-31]. MDA-MB-231 and SUM149-PT, two lines harbouring both NHERF1 mutation and LOH [1], had low NHERF1 protein levels. High expression of NHERF1 was found in some oestrogen receptor (ER)-alpha-positive cells, such as T47D, Zr75.1, and MCF7, consistent with an earlier report that correlated NHERF1 expression with ER-alpha positivity [32]. However, NHERF1 expression does not necessarily follow the ER-alpha status. For example, BT20 cells expressing constitutively active ER-alpha had low NHERF1 expression, whereas NHERF1 was maintained at a high level in ER-alpha-negative MDA-MB-453, MDA-MB-468, and SKBr3 cells, suggesting that mechanisms other than oestrogen induction must exert an effect on NHERF1 expression.
###end p 34
###begin title 35
Growth property changes in response to NHERF1 knockdown
###end title 35
###begin p 36
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 77 82 <span type="species:ncbi:9606">human</span>
One way to determine whether NHERF1 functions as a tumour suppressor gene in human breast cancer is to assess the resultant phenotypic responses by knocking down endogenous NHERF1 expression in NHERF1-high expressors. We used a retrovirus-based system to deliver shRNA to knock down NHERF1 expression in T47D cells. Introduction of NHERF1 shRNA-786 markedly lowered the NHERF1 level (Figure 1b, left panel). By contrast, NHERF1 expression was unaffected by empty retrovirus (Babe). ShRNA can sometimes create non-specific outcomes that are not related to the targeted gene of interest [33]. To ascertain the specificity of phenotypic changes resulting from NHERF1 loss, we also prepared an NHERF1 knockdown line from MCF7 cells by introducing a different targeting sequence, NHERF1 shRNA-910. Introducing shRNA-910 led to virtual elimination of NHERF1 expression in MCF7 cells, in comparison with that of parental cells and Babe control (Figure 1b, right panel).
###end p 36
###begin p 37
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
One frequent response of a given tumour suppressor gene is to inhibit cell proliferation. To determine whether NHERF1 affects cell proliferation, we sought to compare the growth curve of T47D/NHERF-786 and MCF7/NHERF-910 cells with that of their corresponding Babe controls, as determined by MTT assay in 96-well plates. As shown in Figure 2a and 2b, although infection of Babe retrovirus did not affect cell proliferation (parental T47D versus T47D/Babe cells), T47D/NHERF-786 cells grew consistently faster than T47D/Babe control cells, most obviously at days 6 and 7 after plating (by approximately 35%). Similarly, the growth rate of MCF7/NHERF-910 was found to be higher (by 30% to 40%) than that of MCF7/Babe or parental MCF7 cells (Figure 2c). These results suggested an inhibitory effect of NHERF1 on cell proliferation.
###end p 37
###begin p 38
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 219 221 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 322 324 322 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 332 334 332 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 560 562 560 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 586 588 586 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
The DNA synthesis of these cells was also compared using [3H]-thymidine incorporation assays. Knockdown of NHERF1 in T47D cells resulted in a significantly higher DNA synthesis rate than that of the Babe control cells (P = 0.022; Figure 3a). MCF7 cells with NHERF1 knockdown consistently showed accelerated proliferation (P = 4 x 10-6; Figure 3b). The regulatory effect of NHERF1 on cell proliferation was also reflected in anchorage-independent growth. T47D/NHERF-786 cells showed a more efficient colony outgrowth in soft agar than did either parental T47D (P = 0.0043) or T47D/Babe (P = 0.020) cells (Figure 3c), indicating that NHERF1 exhibits growth suppression activity in breast cancer cells.
###end p 38
###begin title 39
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Tumour growth properties in vivo
###end title 39
###begin p 40
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 713 715 711 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 797 799 793 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 805 807 801 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 882 889 878 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 489 494 <span type="species:ncbi:10090">mouse</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
The growth-promotion response as result of NHERF1 knockdown was also examined in a mouse xenograft model. We compared the in vivo growth of T47D cells infected with NHERF1 shRNA-786 retrovirus or vector control. To facilitate tumour formation from T47D cells, which are oestrogen-dependent, we pre-implanted each mouse subcutaneously with a slow-release oestrogen pellet. Two days after pellet implantation, T47D/NHERF-786 or T47D/Babe cells were mixed with Matrigel and injected into the mouse mammary pads. Tumours were visibly established in mice 42 days after injection, when all mice were sacrificed to compare tumour size. As shown in Figure 4a and 4b, tumours formed from T47D/NHERF-786 (72.4 +/- 13.9 mg, n = 10) were significantly larger than those from T47D/Babe cells (37.7 +/- 8.8 mg, n = 8) (P = 0.043), suggesting that lowered NHERF1 expression promotes tumour growth in vivo. None of the tumours was found to metastasise to lung or liver.
###end p 40
###begin title 41
Effect of NHERF1 on cell cycle progression
###end title 41
###begin p 42
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 290 291 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 293 295 293 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 329 330 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 332 334 332 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 396 397 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 399 401 395 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 481 482 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 634 635 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 637 639 625 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 680 681 664 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 722 723 704 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 725 727 707 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 768 769 746 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 805 807 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 901 903 877 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
To examine whether the growth-inhibitory activity of NHERF1 can be attributed to its effect on cell cycle progression, we first compared the cell cycle distribution of asynchronised NHERF1-negative and -positive T47D and MCF7 cells. As shown in Figure 5a, T47D/NHERF-786 cells had a lower G1/G0 and a higher S-phase population (G1/G0 50.4% +/- 0.69%, S 33.3% +/- 0.95%) than Babe control cells (G1/G0 58.6% +/- 1.49%, S 26.0% +/- 1.03%). No significant difference was observed in G2/M-phase populations between the two groups (16.3% +/- 0.64% versus 15.4% +/- 0.47%). Similar results were shown for MCF7 cells with NHERF1 knockdown (G1/G0 37.2% +/- 1.69%, S 42.1% +/- 0.98%, and G2/M 20.4% +/- 0.60% for NHERF-910 versus G1/G0 43.9% +/- 1.75%, S 33.8% +/- 1.39%, and G2/M 22.3% +/- 0.39% for Babe; Figure 5b), which suggested that NHERF1 affects cell cycle progression, probably by stalling cells at G1 phase.
###end p 42
###begin p 43
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 108 110 108 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 163 165 163 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 453 454 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 456 458 456 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 1038 1040 1038 1040 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1220 1221 1220 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
To analyse this possibility in more detail, we serum-starved MCF7 cells to arrest the cell cycle at the G1/G0 phase. One day of starvation led to accumulation of G1 phase from approximately 40% with normal serum condition to more than 70% with serum starvation. The cells were then re-fed with medium containing 10% serum and were allowed to grow for 0 to 29 hours before being harvested for FACS analyses (Figure 6a). At 14 hours after serum feeding, G1/G0 phase cells began advancing to the S phase. Between 14 and 19 hours, a remarkable increase occurred in the S-phase population. Comparing MCF7/Babe and MCF7/NHERF-910 cells, we found that NHERF-910 cells proceeded to S phase significantly faster than their corresponding control. At the 19-hour point, 43.2% and 50.0% of the Babe and NHERF-910 cells, respectively, were in S phase. This trend lasted through 24 hours after serum feeding. At 24 hours, S phase comprised 53.9% and 60.3% of the Babe and NHERF-910 cells, respectively (Figure 6a). In contrast, more cells remained at G1 phase in the Babe (47.8% and 30.8%) than in the NHERF-910 group (42.4% and 23.2%) at the 19- and 24-hour time points, respectively. These results indicated that NHERF1 prohibited G1-to-S cell cycle transition, reflecting the growth-inhibitory activity of NHERF1.
###end p 43
###begin p 44
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 621 622 621 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 927 928 927 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 1365 1367 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 1521 1522 1521 1522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Phosphorylation of Rb protein is one of the most critical processes in enforcing the G1-to-S transition [34]. To further verify whether NHERF1 plays an inhibitory role in G1-to-S cell cycle progression, we compared the Rb protein expression in MCF7/Babe and MCF7/NHERF-910 cells. As shown in Figure 6b, the Rb protein in growth-arrested cells (at 0 hours) was mainly the hypo-phosphorylated form. Corresponding to the beginning of S-phase entry at 14 hours after serum feeding, we detected a high level of hyper-phosphorylated Rb, which gradually receded during the observation period. In consonance with an accelerated G1-to-S transition as a result of NHERF1 loss, MCF7/NHERF-910 cells contained a significantly higher level of hyper-phosphorylated Rb than did the Babe control, most prominently at 14 hours and 19 hours after serum feeding. To explore the mechanism responsible for the difference in Rb phosphorylation and G1-to-S transition, we compared the two groups of cells in their expression of some of the most prominent cell cycle regulatory proteins (Figure 6b). No difference was shown in the level of p27, cdk2, cdk4, or cyclin D1 between the MCF7/NHERF-910 and MCF7/Babe cells. However, we found that the cyclin E level in MCF7/NHERF-910 cells was significantly higher than that in MCF7/Babe at 14 hours and 19 hours after serum stimulation (Figure 6b). A similar result was obtained from another independent experiment. Taken together, these results indicated that NHERF1 knockdown leads to accelerated G1-to-S transition that may involve increased cyclin E content and elevated Rb phosphorylation status.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 172 177 <span type="species:ncbi:9606">human</span>
In the present study, we examined phenotypic changes in response to knockdown of endogenous NHERF1 expression by RNA interference. We found that the knockdown of NHERF1 in human breast cancer cells led to enhanced growth in either an anchorage-dependent or -independent manner. Our study was conducted on a tissue type most relevant to NHERF1 tumour suppressor activity. Results were verified in two breast cancer cell lines and by using two different shRNA targeting sequences. Coupled with our genetic evidence reported earlier, the current functional analyses substantiate NHERF1 as a tumour suppressor gene in mammary gland.
###end p 46
###begin p 47
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 362 363 362 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 399 400 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Phosphorylation of NHERF1 was shown to oscillate during cell cycle progression [35]. However, it was not clear whether NHERF1 plays a role in cell cycle regulation or how phospho-modification on NHERF1 affects cell cycle transition. The current study provides the first direct evidence indicating that the normal NHERF1 function may involve deceleration of the G1-to-S progression. The accelerated G1-to-S progression as a result of NHERF1 knockdown is accompanied by elevated Rb phosphorylation and cyclin E expression (Figure 6). Phosphorylation of Rb is believed to be triggered initially by cyclin D-dependent kinase and then accelerated by cyclin E-cdk2 complex [36,37]. An increase in cyclin E level as a result of NHERF1 loss may speed up the process of Rb phosphorylation and subsequent E2F-mediated gene transcription for S-phase entry. It is not clear at present how decreased NHERF1 expression enhances the cyclin E level. Given the contributing role of cyclin E in mammary gland hyperplasia and tumourigenesis [38,39], it is conceivable that the deregulation of cyclin E as a result of NHERF1 loss contributes to the breast cancer initiation or progression.
###end p 47
###begin p 48
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 282 289 282 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 545 552 541 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 601 603 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1347 1349 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1475 1476 1463 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1733 1740 1721 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 1791 1797 1779 1785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 1870 1872 1858 1860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 1727 1732 <span type="species:ncbi:10090">mouse</span>
###xml 1785 1790 <span type="species:ncbi:9606">human</span>
###xml 1816 1821 <span type="species:ncbi:10090">mouse</span>
Human NHERF1 is thought to be an oestrogen-inducible gene; NHERF1 mRNA and protein were found to be inducible by oestrogen treatment, a response that is blocked by anti-oestrogen [24]. A few half-sites of oestrogen response element (ERE) at the 5'-regulatory sequences of the human NHERF1 gene were found to be responsible for its oestrogen-inducible expression [25]. In light of the key role of oestrogen in mammary gland development and mitogenic responses of many ER-alpha-positive breast cancer cells to oestrogen, it seems paradoxical that NHERF1 would act as a tumour suppressor gene in breast [22]. Our present study did not directly address the relation of NHERF1 to oestrogen. However, when we compared the NHERF1 shRNA and Babe cells (both T47D and MCF7), we found that NHERF1 expression status had no significant effect on oestrogenic responses measured by DNA synthesis and activation of ERE-driven reporter (our unpublished data), suggesting that NHERF1 is at least not an immediate mediator of classic oestrogen responses. Whether NHERF1 precipitates certain oestrogenic effects other than the canonical mitogenic responses remains to be determined. It should be pointed out that NHERF1 expression in breast cancer cells is not necessarily correlated with ER-alpha status. In agreement with observations of primary breast carcinoma [32], our panel of breast cancer cell lines revealed an inconsistent relationship between NHERF1 and ER-alpha positivity (Figure 1), suggesting that regulation of NHERF1 expression exists at levels other than oestrogen stimulation. Speculatively, alterations of these factors in mammary gland may cause an imbalance of NHERF1 level that could lead to neoplasia. Interestingly, the mouse NHERF1 gene does not contain the ERE sites found in human NHERF1, and as a result, mouse NHERF1 expression did not respond to oestrogen [40], suggesting a difference in transcriptional regulation among species to control NHERF1 expression.
###end p 48
###begin p 49
###xml 277 284 277 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 334 338 334 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 647 654 647 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
The study presented here recapitulated the putative tumour suppressor activity of NHERF1 in a cell culture model. A true test of the NHERF1 effect on mammary tumourigenesis, however, would be to analyse mammary gland development and susceptibility of mammary carcinogenesis in NHERF1 knockout mice [41]. Recently, we found that NHERF1-/- mice displayed elevated ductal side branching and extensive mammary gland hyperplasia (our unpublished data). This observation is consistent with the data of this study, which indicate that NHERF1 suppresses cell growth at the mammary site. Whether the disturbance of mammary gland development as a result of NHERF1 gene loss is sufficient to increase breast cancer incidence needs to be investigated.
###end p 49
###begin p 50
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Although our study addressed the biologic effect of NHERF1 on the proliferation of breast cancer cells, it remains unclear which NHERF1-associated pathway, among all NHERF1-interacting partners, is responsible for the NHERF1 tumour suppressor function. We reported earlier that NHERF1 interacted with SYK and merlin [1]. The tumourigenic mutations of NHERF1 partially or completely disrupt the binding of SYK or merlin, both of which are tumour suppressors [19,20,42,43], suggesting that NHERF1 converges in a pathway mediated by the two tumour suppressors. Recently, NHERF1 was reported to interact with PDGFR and PTEN (phosphatase and tensin homologue [mutated in multiple advanced cancers 1]), forming a ternary complex [44]. NHERF1 was hypothesised to assist in recruitment of PTEN to attenuate the PI3K (phosphoinositide-3 kinase) activity initiated by PDGF. Although the hypothesis contrasts with the cooperative effect of NHERF1 on PDGF signaling as suggested by some earlier studies [9,21], this mechanism is consistent with the tumour suppressor activity presented in this study. Whether the negative regulation of growth factor signaling by NHERF1 is responsible for the NHERF1 tumour suppressor function in mammary gland remains to be determined.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
By functional analyses, we show for the first time that NHERF1 possesses growth suppressor activity. We further show that the G1-to-S cell cycle progression is accelerated by NHERF1 knockdown, a phenotype that is accompanied by increased levels of cyclin E and phosphorylated Rb. Based on our published genetic evidence implicating NHERF1 as a tumour suppressor gene [1], we propose that one of the functional activities responsible for its tumour suppressor role is proliferative suppression of mammary epithelial cells. Together, our findings suggest that NHERF1 constitutes a proliferation control pathway in breast cells, justifying further studies of a novel pathway that may represent a potential opportunity for therapeutic intervention.
###end p 52
###begin title 53
Abbreviations
###end title 53
###begin p 54
###xml 292 293 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 295 297 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 332 334 332 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 144 150 <span type="species:ncbi:9913">bovine</span>
ER = oestrogen receptor; ERE = oestrogen response element; ERM = ezrin-radixin-moesin; FACS = fluorescence-activated cell sorting; FBS = foetal bovine serum; LOH = loss of heterozygosity; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF2 = neurofibromatosis-2; NHE3 = Na+/H+ exchanger isoform 3; NHERF1 = Na+/H+ exchanger regulatory factor 1; PBS = phosphate-buffered saline; PDGFR = platelet-derived growth factor receptor; PDZ = PSD-95/Dlg/ZO1; PTEN = phosphatase and tensin homologue (mutated in multiple advanced cancers 1); shRNA = short hairpin RNA; SYK = spleen tyrosine kinase.
###end p 54
###begin title 55
Competing interests
###end title 55
###begin p 56
The authors declare that they have no competing interests.
###end p 56
###begin title 57
Authors' contributions
###end title 57
###begin p 58
YP participated in the experimental design and interpretation of results, carried out experimental procedures, and drafted the manuscript. LW participated in the experimental design. JLD participated in the experimental design and interpretation of results and assisted in writing and editing the manuscript. All authors read and approved the final manuscript.
###end p 58
###begin title 59
Acknowledgements
###end title 59
###begin p 60
This work was supported by National Institutes of Health Grant CA100278. The authors want to thank Drs. Jinsong Liu and Shi Yang for sharing plasmid constructs, Dr. Stephan Ethier for providing cell lines, Ms. Lore Feldman for scientific editing, and Ms. Jin He for artwork.
###end p 60
###begin article-title 61
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 12 14 12 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 61 66 <span type="species:ncbi:9606">human</span>
NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer
###end article-title 61
###begin article-title 62
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
CAMP-mediated inhibition of the renal brush border membrane Na+-H+ exchanger requires a dissociable phosphoprotein cofactor
###end article-title 62
###begin article-title 63
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
cAMP-mediated inhibition of the epithelial brush border Na+/H+ exchanger, NHE3, requires an associatedregulatoryprotein
###end article-title 63
###begin article-title 64
Peptide binding consensus of the NHERF-PDZ1 domain match the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR)
###end article-title 64
###begin article-title 65
Regulation of cystic fibrosis transmembrane conductance regulator single-channel gating by bivalent PDZ-domain-mediated interaction
###end article-title 65
###begin article-title 66
An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton
###end article-title 66
###begin article-title 67
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange
###end article-title 67
###begin article-title 68
A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor
###end article-title 68
###begin article-title 69
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Platelet-derived growth factor receptor association with Na+/H+ exchanger regulatory factor potentiates receptor activity
###end article-title 69
###begin article-title 70
A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration
###end article-title 70
###begin article-title 71
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 20 22 20 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Basolateral Na+/HCO3- cotransport activity is regulated by the dissociable Na+/H+ exchanger regulatory factor
###end article-title 71
###begin article-title 72
Association of mammalian Trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF
###end article-title 72
###begin article-title 73
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Regulation of phospholipase C-beta 3 activity by Na+/H+ exchanger regulatory factor 2
###end article-title 73
###begin article-title 74
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
G protein-coupled receptor kinase 6A phosphorylates the Na+/H+ exchanger regulatory factor via a PDZ domain-mediated interaction
###end article-title 74
###begin article-title 75
Yes-associated protein 65 localizes p62c-Yes to the apical compartment of airway epithelia by association with EBP50
###end article-title 75
###begin article-title 76
EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma
###end article-title 76
###begin article-title 77
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
NHERF, a regulatory cofactor for Na+-H+ exchanger, is a common interactor for merlin and ERM (MERM) proteins
###end article-title 77
###begin article-title 78
Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family
###end article-title 78
###begin article-title 79
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2
###end article-title 79
###begin article-title 80
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor
###end article-title 80
###begin article-title 81
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Ligand-induced recruitment of Na+/H+-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF
###end article-title 81
###begin article-title 82
Expanding the role of NHERF, a PDZ-domain containing protein adaptor, to growth regulation
###end article-title 82
###begin article-title 83
Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma
###end article-title 83
###begin article-title 84
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Estrogen receptor regulation of the Na+/H+ exchanger regulatory factor
###end article-title 84
###begin article-title 85
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Estrogen receptor inducibility of the human Na+/H+ exchanger regulatory factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene involving multiple half-estrogen response elements
###end article-title 85
###begin article-title 86
Evidence of prooncogenic activity of MKK4 in breast and pancreatic tumors
###end article-title 86
###begin article-title 87
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression
###end article-title 87
###begin article-title 88
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer
###end article-title 88
###begin article-title 89
Further evidence to support the melanocytic origin of MDA-MB-435
###end article-title 89
###begin article-title 90
###xml 52 57 <span type="species:ncbi:9606">human</span>
Systematic variation in gene expression patterns in human cancer cell lines
###end article-title 90
###begin article-title 91
Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line
###end article-title 91
###begin article-title 92
NHERF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas
###end article-title 92
###begin article-title 93
Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells
###end article-title 93
###begin article-title 94
Cancer cell cycles
###end article-title 94
###begin article-title 95
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Phosphorylation and cell cycle-dependent regulation of Na+/H+ exchanger regulatory factor-1 by Cdc2 kinase
###end article-title 95
###begin article-title 96
Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation
###end article-title 96
###begin article-title 97
###xml 72 77 <span type="species:ncbi:9606">human</span>
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins
###end article-title 97
###begin article-title 98
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E
###end article-title 98
###begin article-title 99
Cyclin E as a prognostic and predictive marker in breast cancer
###end article-title 99
###begin article-title 100
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
Molecular cloning of the cDNA and promoter sequences for the mouse sodium-hydrogen exchanger regulatory factor
###end article-title 100
###begin article-title 101
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting
###end article-title 101
###begin article-title 102
###xml 55 60 <span type="species:ncbi:9606">human</span>
The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells
###end article-title 102
###begin article-title 103
###xml 55 60 <span type="species:ncbi:9606">human</span>
Hypermethylation leads to silencing of the SYK gene in human breast cancer
###end article-title 103
###begin article-title 104
PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling
###end article-title 104
###begin title 105
Figures and Tables
###end title 105
###begin p 106
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 18 20 18 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 94 98 94 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 264 268 261 265 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 341 346 <span type="species:ncbi:9606">human</span>
Knockdown of Na+/H+ exchanger regulatory factor 1 (NHERF1) expression in breast cancer cells. (a) Breast cancer cell lines, as indicated, were analysed for NHERF1 expression by immunoblotting. Blots were stripped and re-probed with beta-actin for loading control. (b) Short hairpin RNA (shRNA) sequences targeting two different positions of human NHERF1 mRNA, NHERF-786 and NHERF-910, were retrovirally transduced in T47D and MCF7 cells, as shown. Cells were also infected with empty virus (Babe) to be used as a control. Cells that expressed NHERF1 shRNA sequences were selected by 0.5 mug/ml of puromycin. NHERF1 expression in MCF7 and T47D stable cells and their parental lines was examined by immunoblotting. alpha-Tubulin blotting was used for normalisation.
###end p 106
###begin p 107
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 92 96 92 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 234 238 234 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 515 519 515 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 597 600 597 600 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 681 683 681 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 710 712 710 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Growth of T47D and MCF7 cells with Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown. (a) Representative phase-contrast view of monolayer culture of T47D/NHERF-786 cells in comparison with T47D/Babe control, prior to MTT assay. (b) Growth-rate comparison of T47D/NHERF-786 and T47D/Babe cells by MTT assay. Cells cultured in 96-well plates were allowed to grow for 1 to 7 days before MTT reagents were added. The metabolic products of MTT deposited in cells were measured by optical density (O.D.) at 570 nm. (c) MCF7/NHERF-910 and MCF7/Babe cells were measured by MTT assay as described in (b). The growth curve is representative of at least three independent experiments. *P < 0.05 versus Babe cells. #P < 0.05 versus parental cells. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
###end p 107
###begin p 108
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 13 15 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 149 155 149 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a,b) </bold>
###xml 177 181 177 181 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 190 194 190 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 405 407 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 418 420 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 429 433 427 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 516 517 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 874 876 865 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 886 888 877 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Lowered Na+/H+ exchanger regulatory factor 1 (NHERF1) expression leads to increased proliferation in an anchorage-dependent and -independent manner. (a,b) NHERF1 knockdown T47D (a) and MCF7 (b) cells were pulsed with [3H]-thymidine to assay for DNA incorporation. Data are presented as means +/- standard error, arbitrarily setting Babe at 100%. The average of three independent experiments was plotted. *P < 0.05, ***P < 0.001. (c) Soft-agar assay. Parental T47D, Babe control, and NHERF-786 knockdown cells (1 x 104) were suspended in 1 ml of 1x culture medium that contained 0.35% agarose. The suspension was added on top of 4 ml of solidified 0.7% agarose. Plated cells were incubated for 20 days at 37degreesC. Formed colonies larger than 50 mum in diameter were counted. Assays were performed in triplicate. The average of three independent experiments is presented. *P < 0.05, **P < 0.01, in comparison with T47D/NHERF-786.
###end p 108
###begin p 109
###xml 191 193 191 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 218 220 218 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 313 315 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 385 389 385 389 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 423 426 423 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 477 479 475 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 35 44 <span type="species:ncbi:10090">nude mice</span>
###xml 54 63 <span type="species:ncbi:10090">nude mice</span>
###xml 298 303 <span type="species:ncbi:10090">mouse</span>
Tumour growth after injection into nude mice. Athymic nude mice were pre-implanted subcutaneously with oestrogen pellets to support tumour establishment. Three tenths of a million T47D/Babe (n = 10) or T47D/NHERF-786 (n = 8) cells were injected into both sides of the mammary fat pads of each nude mouse (1.5 x 106 on each side). Forty-two days after injection, tumours were dissected (a) and weighed for growth comparison (b). Data are presented as means +/- standard error. *P < 0.05.
###end p 109
###begin p 110
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 94 98 94 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 412 416 412 416 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 595 597 593 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 607 609 605 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 316 322 <span type="species:ncbi:9913">bovine</span>
Effect of Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown on cell cycle distribution. (a) The cell cycle distribution of asynchronous T47D cells (NHERF1 knockdown and Babe control) was determined by fluorescence-activated cell sorting (FACS) analyses. Cells were cultured in media supplemented in 10% foetal bovine serum before being trypsinised, fixed in 75% ethanol, and stained with propidium iodide. (b) Cell cycle distribution of MCF7/NHERF-910 and MCF7/Babe cells was assessed by FACS. Three independent experiments were conducted. Data are presented as means +/- standard error. *P < 0.05, **P < 0.01, as compared with Babe cells.
###end p 110
###begin p 111
###xml 16 17 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 95 99 95 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 202 203 202 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 205 207 205 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 428 432 428 432 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 278 284 <span type="species:ncbi:9913">bovine</span>
Stimulation of G1-to-S progression by Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown. (a) MCF7/NHERF-910 and MCF7/Babe cells were cultured in serum-free media for 1 day to accumulate cells at G1/G0 phase. Cells were then re-fed with medium supplemented with 10% foetal bovine serum for 0, 14, 19, 24, and 29 hours, when cells were trypsinised for fluorescence-activated cell sorting analyses of cell cycle progression. (b) Cells harvested at various time points were lysed for immunoblotting analyses of Rb, p27, cdk2, cdk4, cyclin D1, and cyclin E expression. Hyper-phosphorylated and hypo-phosphorylated forms of Rb are indicated by arrow and arrowhead, respectively. Membranes were also probed with NHERF1 for knockdown verification and with beta-actin for loading control. The result presented was representative of two independent experiments.
###end p 111

